% 0期刊文章%关根身上,狮子座%一个攻击,Beatriz % Fabro,米菲r % Cipolatt, Machado Murillo m . %,拉斐尔·r·g . % Durigon,爱迪生Parolo l . %, Edino %佩莱格里尼,何塞奥古斯托维亚纳s %滨v %施瓦兹,帕特里夏·%葡京,蒂亚戈c %多拉,何塞·米格尔·s % Portich,茱莉亚p %巴斯,亚历山德拉A %新罗,卢西亚Balsan %,Almeri M. %A Schirmer, Felipe da-Silva %A Franz, Juliana P. M. %A da-Silveira, Luciana M. %A Breunig, Raquel C. %A Petersen, Viviana %A Sosnoski, Monalisa %A Mesquita, Nanci F. %A Volpato, Fabiana Caroline Z. %A Sganzerla, Daniel %A Falavigna, Maicon %A Rosa, Regis G. A Zavascki，在2019冠状病毒病(COVID-19)住院患者中，康复期血浆(CP)治疗的效果仍不确定。本研究探讨CP对这些患者临床改善的作用。方法:这是一项由研究者发起、随机、平行、开放标签、优势的临床试验。患者被随机(1:1)分配到两个输注CP加标准护理(SOC)或单独SOC。主要结果是入组后28天临床改善的患者比例。结果160例患者(每组80例)完成了试验，其中危重型占66.3%，重症占33.7%。中位年龄为60.5岁(四分位区间[IQR]， 48-68)， 58.1%为男性，从症状发作到随机化的中位时间为10天(IQR, 8-12)。133例(83.1%)患者在基线时出现了>1:80的中和抗体。 The proportion of patients with clinical improvement on day 28 was 61.3% in the CP+SOC and 65.0% in the SOC group (difference, −3.7%; 95% Confidence Interval [CI], −18.8%-11.3%). The results were similar in the subgroups of severe and critically ill. There was no significant difference between CP+SOC and SOC groups in prespecified secondary outcomes, including 28-day mortality, days alive and free of respiratory support and duration of invasive ventilatory support. Inflammatory and other laboratorial markers values on days 3, 7 and 14 were similar between groups.Conclusions CP+SOC did not result in a higher proportion of clinical improvement on at day 28 in hospitalised patients with COVID-19 compared to SOC alone.In this open-label, randomised clinical trial, two infusions of convalescent plasma therapy plus standard of care compared to standard of care did not result in a higher proportion of clinical improvement on day 28 in hospitalized patients with severe COVID-19. %U //www.qdcxjkg.com/content/erj/early/2021/07/29/13993003.01471-2021.full.pdf